Effects of Aging on Primary and Secondary Vaccine Responses

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
InfluenzaHepatitis ATyphoidHealthy Adults
Interventions
BIOLOGICAL

Fluzone® quadrivalent

IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.

BIOLOGICAL

Fluzone High Dose

High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Fluad

Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Vaqta

Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Typhim Vi

Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Vivotif

One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.

Trial Locations (1)

94305

Stanford LPCH Vaccine Program, Stanford

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03312699 - Effects of Aging on Primary and Secondary Vaccine Responses | Biotech Hunter | Biotech Hunter